DK1855657T3 - Doseringsform indeholdende oxycodon og naloxon - Google Patents

Doseringsform indeholdende oxycodon og naloxon

Info

Publication number
DK1855657T3
DK1855657T3 DK06708567.0T DK06708567T DK1855657T3 DK 1855657 T3 DK1855657 T3 DK 1855657T3 DK 06708567 T DK06708567 T DK 06708567T DK 1855657 T3 DK1855657 T3 DK 1855657T3
Authority
DK
Denmark
Prior art keywords
naloxone
dosage form
sub
form containing
containing oxycodone
Prior art date
Application number
DK06708567.0T
Other languages
English (en)
Inventor
Petra Leyendecker
Michael Hopp
Kevin Smith
Original Assignee
Euro Celtique Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34933990&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1855657(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa
Application granted granted Critical
Publication of DK1855657T3 publication Critical patent/DK1855657T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
DK06708567.0T 2005-02-28 2006-02-28 Doseringsform indeholdende oxycodon og naloxon DK1855657T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05004377A EP1695700A1 (en) 2005-02-28 2005-02-28 Dosage form containing oxycodone and naloxone
PCT/EP2006/060341 WO2006089973A2 (en) 2005-02-28 2006-02-28 Dosage form containing oxycodone and naloxone

Publications (1)

Publication Number Publication Date
DK1855657T3 true DK1855657T3 (da) 2011-10-17

Family

ID=34933990

Family Applications (2)

Application Number Title Priority Date Filing Date
DK06708567.0T DK1855657T3 (da) 2005-02-28 2006-02-28 Doseringsform indeholdende oxycodon og naloxon
DK200700248U DK200700248U3 (da) 2005-02-28 2007-09-27 Doseringsform indeholdende oxycodon og naloxon

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK200700248U DK200700248U3 (da) 2005-02-28 2007-09-27 Doseringsform indeholdende oxycodon og naloxon

Country Status (27)

Country Link
US (5) US20080145429A1 (da)
EP (5) EP1695700A1 (da)
JP (2) JP2008531650A (da)
KR (1) KR20070107805A (da)
CN (2) CN104027297A (da)
AT (1) ATE517611T1 (da)
AU (2) AU2006217870B2 (da)
BR (1) BRPI0607975A2 (da)
CA (3) CA2599156C (da)
CY (1) CY1111967T1 (da)
DE (2) DE202006020095U1 (da)
DK (2) DK1855657T3 (da)
ES (1) ES2370409T3 (da)
FI (1) FI7750U1 (da)
HK (1) HK1111604A1 (da)
HR (1) HRP20110775T1 (da)
IL (2) IL185514A0 (da)
ME (1) ME01262B (da)
MX (1) MX2007010494A (da)
NZ (1) NZ588875A (da)
PL (1) PL1855657T3 (da)
PT (1) PT1855657E (da)
RS (1) RS51984B (da)
RU (1) RU2428985C2 (da)
SI (1) SI1855657T1 (da)
UA (1) UA93543C2 (da)
WO (1) WO2006089973A2 (da)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6277384B1 (en) 1997-12-22 2001-08-21 Euro-Celtique S.A. Opioid agonist/antagonist combinations
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
CN1525851A (zh) 2001-05-11 2004-09-01 ������ҩ�����޹�˾ 抗滥用阿片样物质控释剂型
ES2569262T3 (es) 2001-10-18 2016-05-09 Nektar Therapeutics Conjugados poliméricos de antagonistas de opioides
MXPA04009713A (es) 2002-04-05 2005-01-11 Euro Celtique Sa Preparacion farmaceutica que contiene oxicodona y naloxona.
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
EP1604667A1 (en) * 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the restless leg syndrome
EP1604666A1 (en) 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
EP2319499A1 (en) * 2005-01-28 2011-05-11 Euro-Celtique S.A. Alcohol resistant dosage forms
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
EP1695700A1 (en) 2005-02-28 2006-08-30 Euro-Celtique S.A. Dosage form containing oxycodone and naloxone
EP1702558A1 (en) 2005-02-28 2006-09-20 Euro-Celtique S.A. Method and device for the assessment of bowel function
DE202006018609U1 (de) * 2006-08-29 2007-05-16 Euro-Celtique S.A. Verwendung von Opioidformulierungen in nadellosen Vorrichtungen zur Medikamentenverabreichung
EP2097083A2 (en) * 2006-11-07 2009-09-09 Nektar Therapeutics AL, Corporation Dosage forms and co-administration of an opioid agonist and an opioid antagonist
US20090004231A1 (en) 2007-06-30 2009-01-01 Popp Shane M Pharmaceutical dosage forms fabricated with nanomaterials for quality monitoring
EP2042176A1 (en) * 2007-09-26 2009-04-01 Euro-Celtique S.A. Use of a combination of an opioid agonist and an opioid antagonist for the treatment of Crohn's disease
CN101969930A (zh) 2007-12-17 2011-02-09 莱博法姆公司 防滥用控制释放制剂
US8383152B2 (en) 2008-01-25 2013-02-26 Gruenenthal Gmbh Pharmaceutical dosage form
HUE030803T2 (en) 2008-05-09 2017-06-28 Gruenenthal Gmbh Process for the preparation of an intermediate powder formulation and a final solid dosage form using a spraying step \ t
PE20110422A1 (es) * 2008-07-07 2011-07-01 Euro Celtique Sa Composicion farmaceutica que comprende antagonistas opioides
CA2746888C (en) 2008-12-16 2015-05-12 Labopharm (Barbados) Limited Misuse preventative, controlled release formulation
MY152279A (en) * 2009-03-10 2014-09-15 Euro Celtique Sa Immediate release pharmaceutical compositions comprising oxycodone and naloxone
AR077420A1 (es) 2009-07-22 2011-08-24 Gruenenthal Gmbh Forma de dosificacion resistente a la manipulacion para opiaceos sensibles a la oxidacion
EP2456427B1 (en) 2009-07-22 2015-03-04 Grünenthal GmbH Hot-melt extruded controlled release dosage form
US8475832B2 (en) 2009-08-07 2013-07-02 Rb Pharmaceuticals Limited Sublingual and buccal film compositions
EP2531176B1 (en) 2010-02-03 2016-09-07 Grünenthal GmbH Preparation of a powdery pharmaceutical composition by means of an extruder
BR112012028656A2 (pt) 2010-05-10 2016-08-09 Euro Celtique Sa combinação de grânulos carregados ativos com ativos adicionais
AU2011252040C1 (en) 2010-05-10 2015-04-02 Euro-Celtique S.A. Manufacturing of active-free granules and tablets comprising the same
NZ700732A (en) 2010-05-10 2015-08-28 Euro Celtique Sa Pharmaceutical compositions comprising hydromorphone and naloxone
PE20131101A1 (es) * 2010-08-13 2013-09-23 Euro Celtique Sa Formulaciones estables al almacenamiento de oxicodona y naloxona
JP5933553B2 (ja) 2010-09-02 2016-06-15 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング アニオン性ポリマーを含む不正使用抵抗性剤形
ES2486791T3 (es) 2010-09-02 2014-08-19 Grünenthal GmbH Forma de dosificación resistente a la manipulación que comprende una sal inorgánica
MX354125B (es) * 2010-12-28 2018-02-14 Euro Celtique Sa Combinacion de un agonista opioide y un antagonista opioide en el tratamiento de la enfermedad de parkinson.
LT2736495T (lt) 2011-07-29 2017-11-10 Grünenthal GmbH Sugadinimui atspari tabletė, pasižyminti greitu vaisto atpalaidavimu
RS56527B1 (sr) 2011-07-29 2018-02-28 Gruenenthal Gmbh Tableta za trenutno oslobađanje leka rezistentna na zloupotrebu
CA2864949A1 (en) 2012-02-28 2013-09-06 Grunenthal Gmbh Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
AR092820A1 (es) 2012-04-17 2015-05-06 Purdue Pharma Lp Sistemas y metodos para tratar una respuesta farmacodinamica adversa inducida por opioides, unidad de dosis, kit
EP2838512B1 (en) 2012-04-18 2018-08-22 Grünenthal GmbH Tamper resistant and dose-dumping resistant pharmaceutical dosage form
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
JP6466417B2 (ja) 2013-05-29 2019-02-06 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 二峰性放出プロファイルを有する改変防止（ｔａｍｐｅｒ−ｒｅｓｉｓｔａｎｔ）剤形
MX371432B (es) 2013-05-29 2020-01-30 Gruenenthal Gmbh Forma de dosificacion resistente al uso indebido que contiene una o mas particulas.
MX368846B (es) 2013-07-12 2019-10-18 Gruenenthal Gmbh Forma de dosificación resistente a la alteración que contiene polímero de acetato de etilen-vinilo.
UA116567C2 (uk) 2013-07-23 2018-04-10 Євро-Селтік С.А. Комбінація оксикодону та налоксону для застосування в лікуванні болю у пацієнтів, які страждають від болю та захворювання, що призводить до дисбактеріозу кишечнику та/або підвищує ризик кишкової бактеріальної транслокації
BR112016009749A8 (pt) 2013-11-13 2018-01-30 Euro Celtique Sa hidromorfona e naloxona para tratamento de dor e síndrome de disfunção intestinal opioide
EP3073994A1 (en) 2013-11-26 2016-10-05 Grünenthal GmbH Preparation of a powdery pharmaceutical composition by means of cryo-milling
US9192570B2 (en) 2013-12-20 2015-11-24 AntiOP, Inc. Intranasal naloxone compositions and methods of making and using same
ES2631504B1 (es) 2014-03-14 2018-11-28 Opiant Pharmaceuticals, Inc. Medicamentos de administración nasal y métodos para su uso
US9561177B2 (en) 2014-03-14 2017-02-07 Adapt Pharma Limited Nasal drug products and methods of their use
US9480644B2 (en) 2014-03-14 2016-11-01 Opiant Pharmaceuticals, Inc. Nasal drug products and methods of their use
US10085937B2 (en) 2014-03-14 2018-10-02 Adapt Pharma Limited Nasal drug products and methods of their use
EP3142646A1 (en) 2014-05-12 2017-03-22 Grünenthal GmbH Tamper resistant immediate release capsule formulation comprising tapentadol
AU2015266117A1 (en) 2014-05-26 2016-11-24 Grunenthal Gmbh Multiparticles safeguarded against ethanolic dose-dumping
EP3174534A1 (en) * 2014-08-01 2017-06-07 KRKA, d.d., Novo mesto Pharmaceutical formulation comprising an opioid agonist and an opioid antagonist prepared by melt granulation using lipid esters
US9849124B2 (en) 2014-10-17 2017-12-26 Purdue Pharma L.P. Systems and methods for treating an opioid-induced adverse pharmacodynamic response
US20160256451A1 (en) * 2015-03-06 2016-09-08 Develco Pharma Schweiz Ag Dosage of naloxone
US20160256453A1 (en) * 2015-03-06 2016-09-08 Develco Pharma Schweiz Ag Opioid receptor antagonist for use in treating patients with severe constipation induced by high opiate dosage regimen
EA035434B1 (ru) 2015-04-24 2020-06-15 Грюненталь Гмбх Защищенная от применения не по назначению лекарственная форма с немедленным высвобождением и устойчивостью к экстракции растворителями
WO2016193456A2 (en) * 2015-06-03 2016-12-08 Develco Pharma Schweiz Ag Opioid receptor antagonist for use in treating patients with severe constipation
JP2018526414A (ja) 2015-09-10 2018-09-13 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 乱用抑止性の即放性製剤を用いた経口過剰摂取に対する保護
US9861629B1 (en) 2015-10-07 2018-01-09 Banner Life Sciences Llc Opioid abuse deterrent dosage forms
US10335405B1 (en) 2016-05-04 2019-07-02 Patheon Softgels, Inc. Non-burst releasing pharmaceutical composition
US10335375B2 (en) 2017-05-30 2019-07-02 Patheon Softgels, Inc. Anti-overingestion abuse deterrent compositions
US20210043293A1 (en) * 2019-08-05 2021-02-11 RxAssurance Corporation (d/b/a OpiSafe) Techniques for providing interactive clinical decision support for drug dosage reduction
US20240131022A1 (en) * 2022-03-11 2024-04-25 John Abernethy Opioid overdose reversal mixtures

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3173876A (en) * 1960-05-27 1965-03-16 John C Zobrist Cleaning methods and compositions
NL271831A (da) * 1960-11-29
US3276586A (en) * 1963-08-30 1966-10-04 Rosaen Filter Co Indicating means for fluid filters
NL6714885A (da) * 1967-11-02 1969-05-06
US3541006A (en) * 1968-07-03 1970-11-17 Amicon Corp Ultrafiltration process
US3773955A (en) * 1970-08-03 1973-11-20 Bristol Myers Co Analgetic compositions
FR2183546B1 (da) * 1972-05-10 1975-06-20 Servier Lab
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US3916889A (en) * 1973-09-28 1975-11-04 Sandoz Ag Patient ventilator apparatus
US3966940A (en) 1973-11-09 1976-06-29 Bristol-Myers Company Analgetic compositions
GB1478759A (en) * 1974-11-18 1977-07-06 Alza Corp Process for forming outlet passageways in pills using a laser
US3966040A (en) * 1975-03-05 1976-06-29 Hazelwood John E Combined vibratory feeder drive unit, vibratory feeder bowl, and parts separator
US4077407A (en) * 1975-11-24 1978-03-07 Alza Corporation Osmotic devices having composite walls
US4126684A (en) * 1976-02-11 1978-11-21 Ciba-Geigy Corporation 4-amino-3-p-halophenylbutyric acids and their derivatives used in the control of narcotic abuse
US4063064A (en) * 1976-02-23 1977-12-13 Coherent Radiation Apparatus for tracking moving workpiece by a laser beam
US4285987A (en) * 1978-10-23 1981-08-25 Alza Corporation Process for manufacturing device with dispersion zone
US4200098A (en) * 1978-10-23 1980-04-29 Alza Corporation Osmotic system with distribution zone for dispensing beneficial agent
US4457933A (en) * 1980-01-24 1984-07-03 Bristol-Myers Company Prevention of analgesic abuse
GB8332556D0 (en) 1983-12-06 1984-01-11 Reckitt & Colmann Prod Ltd Analgesic compositions
US4668685A (en) * 1984-07-05 1987-05-26 E.I. Du Pont De Nemours And Company Substituted benzoate ester prodrug derivatives of 3-hydroxymorphinans, which are analgesics or narcotic antagonists
US4861598A (en) * 1986-07-18 1989-08-29 Euroceltique, S.A. Controlled release bases for pharmaceuticals
DE3812567A1 (de) * 1988-04-15 1989-10-26 Basf Ag Verfahren zur herstellung pharmazeutischer mischungen
EP0352361A1 (en) 1988-07-29 1990-01-31 The Rockefeller University Method of treating patients suffering from chronic pain or chronic cough
US5236714A (en) * 1988-11-01 1993-08-17 Alza Corporation Abusable substance dosage form having reduced abuse potential
US5656295A (en) * 1991-11-27 1997-08-12 Euro-Celtique, S.A. Controlled release oxycodone compositions
US5266331A (en) * 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
US5681585A (en) * 1991-12-24 1997-10-28 Euro-Celtique, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5273760A (en) * 1991-12-24 1993-12-28 Euroceltigue, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5472712A (en) * 1991-12-24 1995-12-05 Euroceltique, S.A. Controlled-release formulations coated with aqueous dispersions of ethylcellulose
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US5286493A (en) * 1992-01-27 1994-02-15 Euroceltique, S.A. Stabilized controlled release formulations having acrylic polymer coating
US5968551A (en) * 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US5324351A (en) * 1992-08-13 1994-06-28 Euroceltique Aqueous dispersions of zein and preparation thereof
IL109460A (en) * 1993-05-10 1998-03-10 Euro Celtique Sa Controlled release formulation comprising tramadol
IL110014A (en) * 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics
DE4325465B4 (de) * 1993-07-29 2004-03-04 Zenz, Michael, Prof. Dr.med. Orales pharmazeutisches Präparat für die Schmerztherapie
US5411745A (en) * 1994-05-25 1995-05-02 Euro-Celtique, S.A. Powder-layered morphine sulfate formulations
US5866154A (en) * 1994-10-07 1999-02-02 The Dupont Merck Pharmaceutical Company Stabilized naloxone formulations
US5965161A (en) * 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
US5865161A (en) * 1995-01-04 1999-02-02 Bruce; Norman R. Baseball pitching device
US20020006964A1 (en) * 1995-05-16 2002-01-17 Young James W. Methods of using and compositions comprising (+) sibutramine optionally in combination with other pharmacologically active compounds
DE19651551C2 (de) * 1996-12-11 2000-02-03 Klinge Co Chem Pharm Fab Opioidantagonisthaltige galenische Formulierung
US6207142B1 (en) * 1997-04-14 2001-03-27 Janssen Pharmaceutica N.V. Compositions containing an antifungal and a cationic agent
ATE322892T1 (de) * 1997-07-02 2006-04-15 Euro Celtique Sa Stabilisierte tramadol formulierungen mit verzögerter freisetzung
PL341309A1 (en) * 1997-12-22 2001-04-09 Euro Celtique Method of preventing overdosage of opioidic preparations
US6277384B1 (en) * 1997-12-22 2001-08-21 Euro-Celtique S.A. Opioid agonist/antagonist combinations
US6114326A (en) * 1998-03-27 2000-09-05 Pharmacia & Upjohn Company Use of cabergoline in the treatment of restless legs syndrome
US20030178031A1 (en) * 1999-05-07 2003-09-25 Du Pen, Inc. Method for cancer pain treatment
US7653545B1 (en) * 1999-06-11 2010-01-26 Telstra Corporation Limited Method of developing an interactive system
US20030118641A1 (en) * 2000-07-27 2003-06-26 Roxane Laboratories, Inc. Abuse-resistant sustained-release opioid formulation
DE19938823A1 (de) * 1999-08-19 2001-02-22 Boehringer Ingelheim Pharma Medikamentöse Behandlung des Restless Leg Syndroms
US6258042B1 (en) 1999-09-17 2001-07-10 James S. Factor Visual analog scale and method of use for the diagnosis and/or treatment of physical pain
PT1255547E (pt) * 2000-02-08 2008-11-24 Euro Celtique Sa Composições de libertação controlada contendo agonistas e antagonistas opióides
US6716449B2 (en) * 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
US7223421B2 (en) * 2000-06-30 2007-05-29 Mcneil-Ppc, Inc. Teste masked pharmaceutical particles
AR031152A1 (es) * 2000-10-31 2003-09-10 Upjohn Co Tratamientos nuevos para el sindrome de piernas inquietas
EA006396B1 (ru) * 2001-04-19 2005-12-29 УОРНЕР-ЛАМБЕРТ КОМПАНИ Эл Эл Си Конденсированные бициклические аминокислоты
UA81224C2 (uk) * 2001-05-02 2007-12-25 Euro Celtic S A Дозована форма оксикодону та її застосування
CN1592609A (zh) * 2001-05-11 2005-03-09 恩德制药公司 抗滥用阿片样物质剂型
CN1525851A (zh) * 2001-05-11 2004-09-01 ������ҩ�����޹�˾ 抗滥用阿片样物质控释剂型
PT1416842E (pt) * 2001-07-18 2009-03-31 Euro Celtique Sa Composições farmacêuticas de oxicodona e naloxona
US7332182B2 (en) * 2001-08-06 2008-02-19 Purdue Pharma L.P. Pharmaceutical formulation containing opioid agonist, opioid antagonist and irritant
US20030044458A1 (en) * 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
EP1429787A1 (en) * 2001-09-24 2004-06-23 Ortho-McNeil Pharmaceutical, Inc. Anticonvulsant derivatives useful for the treatment of restless limb syndrome and periodic limb movement disorder
PT1482835E (pt) 2002-03-06 2012-12-26 Euro Celtique Sa Escala analógica para medição da dor
MXPA04009713A (es) 2002-04-05 2005-01-11 Euro Celtique Sa Preparacion farmaceutica que contiene oxicodona y naloxona.
US20030191147A1 (en) * 2002-04-09 2003-10-09 Barry Sherman Opioid antagonist compositions and dosage forms
JP4694207B2 (ja) * 2002-07-05 2011-06-08 コルジウム ファーマシューティカル， インコーポレイテッド オピオイドおよび他の薬物に関する乱用抑止性の薬学的組成物
MY135852A (en) * 2003-04-21 2008-07-31 Euro Celtique Sa Pharmaceutical products
US7700626B2 (en) * 2004-06-04 2010-04-20 Adolor Corporation Compositions containing opioid antagonists
EP1604666A1 (en) * 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
EP1695700A1 (en) 2005-02-28 2006-08-30 Euro-Celtique S.A. Dosage form containing oxycodone and naloxone

Also Published As

Publication number Publication date
US20110172259A1 (en) 2011-07-14
EP2258353A3 (en) 2012-05-09
HRP20110775T1 (hr) 2011-11-30
EP1695700A1 (en) 2006-08-30
PT1855657E (pt) 2011-10-31
DE202006020095U1 (de) 2007-11-08
EP2962686A1 (en) 2016-01-06
DK200700248U3 (da) 2008-02-08
FI7750U1 (fi) 2008-01-22
EP2962686B1 (en) 2019-04-10
EP2258353A2 (en) 2010-12-08
SI1855657T1 (sl) 2011-11-30
DE19167974T1 (de) 2021-12-30
RS51984B (en) 2012-02-29
JP2014169303A (ja) 2014-09-18
US20120225901A1 (en) 2012-09-06
CY1111967T1 (el) 2015-11-04
CN101128191A (zh) 2008-02-20
DK200700248U1 (da) 2007-12-14
HK1111604A1 (en) 2008-08-15
CA2599156A1 (en) 2006-08-31
EP3578173A1 (en) 2019-12-11
MX2007010494A (es) 2008-01-16
US20140031382A1 (en) 2014-01-30
CA2599156C (en) 2012-05-01
ATE517611T1 (de) 2011-08-15
ES2370409T3 (es) 2011-12-15
US20080145429A1 (en) 2008-06-19
JP6235962B2 (ja) 2017-11-22
FIU20070153U0 (fi) 2007-04-13
EP1855657B1 (en) 2011-07-27
CA2768075A1 (en) 2006-08-31
AU2009201019A1 (en) 2009-04-02
RU2428985C2 (ru) 2011-09-20
NZ588875A (en) 2012-02-24
CA2960011A1 (en) 2006-08-31
EP3578173B1 (en) 2022-10-26
IL196539A0 (en) 2011-07-31
AU2006217870B2 (en) 2008-12-18
JP2008531650A (ja) 2008-08-14
RU2007135991A (ru) 2009-04-10
PL1855657T3 (pl) 2012-03-30
AU2009201019B2 (en) 2011-05-26
CN104027297A (zh) 2014-09-10
BRPI0607975A2 (pt) 2009-10-27
UA93543C2 (ru) 2011-02-25
KR20070107805A (ko) 2007-11-07
IL185514A0 (en) 2008-01-06
ME01262B (me) 2013-06-20
US20180008593A1 (en) 2018-01-11
AU2006217870A1 (en) 2006-08-31
EP1855657A2 (en) 2007-11-21
WO2006089973A3 (en) 2006-12-28
WO2006089973A2 (en) 2006-08-31

Similar Documents

Publication Publication Date Title
DK1855657T3 (da) Doseringsform indeholdende oxycodon og naloxon
EA200900260A1 (ru) Гранулы и орально дезинтегрируемые таблетки, содержащие оксикодон
ZA200704130B (en) Protassium salt of an HIV integrase inhibitor
WO2007087395A3 (en) UNSATURATED mTOR INHIBITORS
PT1940839E (pt) Inibidores de piridopirimidinona pi3k alfa
WO2009152356A3 (en) Compounds and compositions useful for the treatment of malaria
GEP20135925B (en) Inhibitors of hedgehog pathway
WO2009156462A3 (en) Organic compounds
TW200833370A (en) Pharmaceutical composition containing low substituted hydroxypropylcellulose
TW200738699A (en) 4-Substituted pyrazoline compounds, their preparation and use as medicaments
ZA200806778B (en) N-Hydroxyacrylamide compounds
RS20050868A (en) Pharmaceutical combinations of a proton pump inhibitor and a compound which modifies gastrointestinal motility
EP1862070A3 (en) Microbicidal composition
GB2421245B (en) Low Dosage Naphthenate Inhibitors
WO2007130507A3 (en) Acute pain medications based on fast acting diclofenac-opioid combinations
WO2008139952A1 (ja) 微小管破壊剤及びそれを含有する癌細胞増殖抑制剤
WO2007115287A3 (en) Combination of organic compounds
WO2006055663A3 (en) The use of novel antibacterial compounds
EP2387885A3 (en) Solid microbicidal composition containing a mixture of 5-chloro-2-methyl-4-isothiazolin-3-one and 2-methyl-4-isothiazolin-3-one
WO2007092741A3 (en) Hydroxylamines and derivatives as anti-angiogenic agents
WO2007139948A3 (en) Imidazoazepinone compounds
GB0618870D0 (en) Organic compounds
NO20042548D0 (no) Impregneringsmiddel til behandling av oppdrettsnoter
IL229418A0 (en) Chemical derivatives of jesmont, pharmaceutical preparations and methods of using them
TW200505868A (en) New synerglstic combinations